Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue	$ 253,573	$ 223,208
Cost of Revenues	474,550	432,370
Gross Loss	(220,977)	(209,162)
Research Revenues		288,002
Net (Loss) Revenue	(220,977)	78,840
Operating Expenses:
Research and Development	691,770	525,563
General and Administrative Expenses	4,241,836	1,303,722
Total Operating Expenses	4,933,606	1,829,285
Loss from Operations	(5,154,583)	(1,750,445)
Interest Expense	(2,286,637)	(3,989,359)
Derivative Expense	(399,725)	(504,613)
Change in Fair Value of Derivative Liabilities	(37,278)	(10,312)
(Loss) Gain on Debt Extinguishment	(1,231,480)	120,683
Change in Fair Value of Promissory Note	5,379,269
Other Expenses, net	(83,116)	(43,238)
Total Interest and Other Income (Expense), net	1,341,033	(4,426,839)
Loss from Operations before Provision for Income Taxes	(3,813,550)	(6,177,284)
Provision for Income Taxes (Note 10)	250	500
Net Loss including Noncontrolling Interest	(3,813,800)	(6,177,784)
Net (Loss) Income – Noncontrolling Interest	(48,098)	3,936
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.	(3,765,702)	(6,181,720)
Comprehensive Loss:
Net Loss	(3,813,800)	(6,177,784)
Unrealized Foreign Currency Translation Gain (Loss)	61,853	(2,127)
Total Comprehensive Loss	(3,751,947)	(6,179,911)
Net (Loss) Income – Noncontrolling Interest	(48,098)	3,936
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.	(3,703,849)	(6,183,847)
Cumulative Dividends on Series A Preferred Stock	(220,714)
Net Loss - attributed to common stockholders	$ (3,924,563)	$ (6,183,847)
Net Loss per Common Share:
Basic and Diluted (in Dollars per share)	$ (0.99)	$ (2.61)
Weighted Average Number of Common Shares Outstanding
Basic and Diluted (in Shares)	3,960,280	2,367,729
Product Revenues – net of Discounts and Rebates
Revenue	$ 253,573	$ 192,913
Service Revenues
Revenue		$ 30,295